mefway and Parkinsonian-Disorders

mefway has been researched along with Parkinsonian-Disorders* in 1 studies

Other Studies

1 other study(ies) available for mefway and Parkinsonian-Disorders

ArticleYear
Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[(18)F]Mefway.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2014, Volume: 94

    The purpose of the present study is to investigate the relationship between dopaminergic neuron destruction and 5-HT system changes in a hemiparkinsonian rat model. We performed PET imaging studies with trans-[(18)F]Mefway in a hemiparkinsonian model of unilateral 6-hydroxydopamine (6-OHDA) rats. Region-of-interests (ROIs) were drawn in the hippocampus (HP) and cerebellum (CB). HP uptake, the ratios of specific binding to non-specific binding in the HP, and non-displaceable binding potential (BPND) in the HP were compared between 6-OHDA and control rats. As a result, unilateral 6-OHDA-lesioned rats exhibited significant bilateral reduction of HP uptake and trans-[(18)F]Mefway BPND compared to the intact control group. Therefore, the results demonstrate that destruction of the dopaminergic system causes the reduction of the serotonergic system.

    Topics: Animals; Dopaminergic Neurons; Fluorine Radioisotopes; Hippocampus; Male; Metabolic Clearance Rate; Parkinsonian Disorders; Piperazines; Pyridines; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution

2014